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The mechanism(s) by which the early EICP27 gene product cooperates with other equine herpesvirus 1 (EHV-1) regulatory proteins to
achieve maximal promoter activity remains unknown. Transient transfection assays revealed that deletion of residues 93–140 of the 470-aa
EICP27 protein substantially diminished its activation of the immediate-early (IE) promoter, whereas deletion of residues 140–470 that
contain a zinc-finger motif abolished this activity. Fluorescence microscopy of cells expressing the full-length EICP27 protein or portions of
this protein revealed that an arginine-rich sequence spanning residues 178–185 mediates nuclear entry. Experiments employing the
mammalian Gal4 two-plasmid system revealed that the EICP27 protein does not possess an independent trans-activation domain (TAD).
Protein–protein interaction assays using purified proteins revealed that residues 124–220 of the EICP27 protein mediate its direct interaction
with TATA box-binding protein (TBP). Partial deletion of this TBP-binding domain attenuated the ability of the EICP27 protein to stimulate
the IE and early EICP0 promoters by 68% and 71%, respectively, indicating the importance of this protein–protein interaction.
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Equine herpesvirus 1 (EHV-1) is a member of the Alpha-
herpesvirinae subfamily that also includes herpes simplex
virus (HSV) types 1 and 2 and varicella zoster virus (VZV).
Our laboratory employs EHV-1 as a model to investigate
aspects of Alphaherpesvirinae gene regulation, pathogenesis,
and persistent infection mediated by defective interfering
(DI) particles (O’Callaghan and Osterrieder, 1999). During
lytic infection, the 78 EHV-1 genes are temporally tran-
scribed as immediate-early (IE), early, leaky late (g1), and
true late (g2) messenger RNA (Breeden et al., 1992; Caugh-
man et al., 1985; Cohen et al., 1975; Gray et al., 1987a,
1987b; Telford et al., 1992) in a manner that is analogous to0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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Texas Southwestern Medical Center, Dallas, TX 75390, USA.the gene regulation programs of other Alphaherpesvirinae
members (Clements et al., 1977; Honess and Roizman, 1974;
Roizman et al., 1975; Weinheimer and McKnight, 1987;
Weir, 2001). Six virally encoded regulatory proteins (the IE
protein; the early EICP0, EICP22, EICP27, and IR2 proteins;
and the late E-TIF) orchestrate the temporal transcription of
the EHV-1 genes. The sole IR1 gene encodes the IE regula-
tory protein that trans-activates early and some late pro-
moters (Smith et al., 1992, 1995), and whose functions are
essential for lytic replication (Garko-Buczynski et al., 1998).
The early EICP0 regulatory protein promiscuously trans-
activates early and late EHV-1 promoters (Bowles et al.,
1997, 2000), but is not essential for viral replication (Yao et
al., 2003). The early EICP22 and EICP27 regulatory proteins
synergize the trans-activation functions of the IE and EICP0
proteins (Bowles et al., 2000; Holden et al., 1995; Kim et al.,
1997; Smith et al., 1993b; Zhao et al., 1995). The early IR2
protein is hypothesized to negatively regulate EHV-1 gene
expression by interfering with the trans-activation function of
the IE protein (Harty and O’Callaghan, 1991; Smith et al.,
1994). The late E-TIF regulatory protein is a tegument protein
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O’Callaghan, 2001; Lewis et al., 1993, 1997).
The early EICP27 (UL5) gene encodes a 470-amino-acid
(aa) phosphoprotein with an apparent molecular weight of
51.4 kDa (Zhao et al., 1992). The EICP27 protein has limited
homology with the ICP27 protein of HSV-1 (32%) and the
IE4 protein of VZV (13%) (Piette et al., 1995; Zhao et al.,
1992). Furthermore, the 3Vend of the EICP27 gene encodes a
conserved zinc-finger motif that was demonstrated to be
functional in its HSV-1 ICP27 homologue (Vaughan et al.,
1992). Transient transfection assays revealed that the EICP27
protein: (i) enhanced gene expression from the IE promoter
(Zhao et al., 1995), (ii) could not alleviate the negative
autoregulation of the IE promoter by the IE protein (Zhao
et al., 1995), (iii) cooperated with the IE protein in trans-
activation of representative early and late viral promotersFig. 1. Expression of the native EICP27 gene and EICP27 truncation and de
representation of the EICP27 protein indicating the amino acid positions of the s
polypeptide is indicated at the left of the figure. (Panel B) Western blot analys
transiently transfected L-M cells. The EICP27 mutants EICP27D291–343, EICP2
EICP27(1–422) yielded less intense bands, suggesting that this region may harbor
EICP27 protein. The sizes of the molecular weight markers (kDa) are indicated a(Smith et al., 1992, 1993b), and (iv) functioned in a syner-
gistic manner with the EICP0 protein to stimulate expression
of a representative early promoter (Bowles et al., 2000).
Interestingly, EICP27 residues 402–470 that encompass
the conserved zinc-finger motif are present within the
EICP22/EICP27 hybrid protein encoded by the genome of
EHV-1 DI particles (Chen et al., 1996; O’Callaghan and
Osterrieder, 1999). EHV-1 infections enriched for DI par-
ticles expressing this EICP22/EICP27 hybrid gene were
shown to result in persistent infection (Dauenhauer et al.,
1982; Gray et al., 1989; Robinson et al., 1980). The
EICP22/EICP27 hybrid gene originated from a homologous
recombination event that involved an identical 8-bp se-
quence present within the EICP22 and EICP27 genes (Chen
et al., 1996; Yalamanchili et al., 1990). Thus, the hybrid
gene also encodes EICP22 residues 1–196, which harborsletion mutants in transiently transfected L-M cells. (Panel A) Schematic
tructural motifs. The amino acid sequence deleted in each EICP27 mutant
es of full-length EICP27 and EICP27 mutant polypeptides synthesized in
7D343–395, EICP27D380–402, EICP27D216–446, EICP27(1–281), and
the majority of the immunodominant epitopes present within the full-length
t the left of the panel.
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protein-binding (Chen et al., 1996; Derbigny et al., 2000).
The hybrid protein was demonstrated to repress both acti-
vation of the IE promoter and trans-activation of early
promoters by the IE protein; however, the EICP22/EICP27
protein stimulated the ability of the IE protein to trans-
activate late promoters (Chen et al., 1999). How the EICP27
zinc-finger contributes to the functions of the EICP27
protein during lytic infection or to those of the hybrid
protein during persistent infection remains unknown.
The mechanism(s) by which the EICP27 protein
increases the expression of viral genes is obscure; there-
fore, EICP27 deletion mutants were tested in transient
transfection assays to delineate the functional regions of
this protein. Because the EICP27 protein cooperates with
the IE and EICP0 proteins to activate EHV-1 promoters,
it was of interest to determine if this cooperation was
mediated, at least in part, by an interaction with one or
more cellular transcription factors. In this manuscript, we
document the direct interaction of the EICP27 protein
with TATA box-binding protein (TBP).Results
EICP27 residues 279–470 are essential to enhance IE
promoter activity
Prior data from transient transfection assays indicated that
the EICP27 protein independently enhances the activity of
the IE promoter (Smith et al., 1993b; Zhao et al., 1995). To
map the domain(s) within the EICP27 protein necessary for
this function, a panel of EICP27 deletion and truncation
mutants was constructed (Fig. 1A). To facilitate the detection
of the EICP27 deletion mutants, a polyclonal antibody thatFig. 2. Detection of the EICP27 protein with anti-EICP27 protein antibody by We
from mock-infected or EHV-1 (strain KyA)-infected RK-13 and equine ETCC c
luciferase protein or EICP27 protein. Asterisks denote proteins nonspecifically reco
markers (kDa) are indicated at the left of each panel.recognizes the full-length EICP27 protein (aa 1–470) was
generated. Western blot assays showed that this antibody
detects the EICP27 protein produced during EHV-1 infec-
tions (Fig. 2A) and by in vitro transcription/translation
reactions (Fig. 2B). Extracts of L-M cells that were trans-
fected with constructs encoding the EICP27 deletion mutants
were examined by Western blot analysis with the anti-
EICP27 protein polyclonal antibody to verify the expression
of the encoded EICP27 sequence (Fig. 1B). These analyses
revealed that the EICP27 sequence within each construct
expressed a protein of the expected size, and that the protein
was readily detected by Western blotting.
The ability of each EICP27 mutant to enhance expression
of the IE promoter-chloramphenicol Acetyl-transferase
(CAT) reporter chimera, pIE-CAT [pIE (802/+73)], was
compared to that of the native EICP27 in transient transfec-
tion assays. As consistent with previous findings (Smith et al.,
1992), the full-length EICP27 protein enhanced expression
from the IE promoter by 12-fold (Fig. 3, panel A, Bar 2) and
by 9-fold (Fig. 3, panel B, Bar 2). The deletion mutants
EICP27D41–89 and EICP27D89–124 ((Fig. 3, panel A,
Bars and 3 and 5), respectively) enhanced reporter expression
from the IE promoter with efficiencies that were comparable
to that of the native EICP27 protein. An EICP27 deletion
mutant that lacked residues 8–57 activated the IE promoter to
a level comparable to that of the full-length EICP27 protein
(data not shown). The ability of the EICP27D93–140 poly-
peptide to activate the IE promoter was reduced by 68% (Fig.
3, panel A, Bar 4). Conversely, the EICP27 derivatives
EICP27D93–220, EICP27D140–220, EICP27D41–279,
EICP27D291–343, EICP27D343–395, EICP27D380–402,
EICP27D216–446, EICP27(1–281), and EICP27(1–422)
were completely devoid of this functional activity (Fig. 3,
panel B, Bars 3–11, respectively). These results argue that
the sequence spanning aa 1–140 is not essential for thisstern blot analyses. (Panel A) Western blot analysis of cell extracts prepared
ells. (Panel B) Western blot analysis of in vitro transcribed and translated
gnized by the anti-GST-EICP27 antibody. The sizes of the molecular weight
Fig. 3. Mapping the functional domains that enable the EICP27 protein to activate the IE promoter. (Panels A and B) The EICP27 deletion and truncation
mutants were employed in transient transfection assays that tested their ability to activate the IE promoter present in the reporter plasmid IE-CAT [pIE( 802/
+ 73)]. L-M cells were transfected with 0.5 pmol of the reporter plasmid alone (Panels A and B, Bar 1, respectively) or were cotransfected with the reporter
plasmid and 0.3 pmol of the indicated EICP27 expression plasmid (Panel A, Bars 2–5 and Panel B, Bars 2–11). In some experiments, the cloning plasmid
pSV-Sport1 was included as a negative control (data not shown). The data were compiled from the averages of three independent experiments in which each
sample was assessed independently in triplicate. The data are presented as the average percent acetylation of the total amount of 14C-labeled chloramphenicol
that was included in each reaction. The error bars indicate the standard deviations.
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residues 140–220 and 279–470 are essential.
EICP27 residues 178–185 harbor a nuclear localization
signal (NLS)
The ineffectiveness of some of the EICP27 mutants to
activate the IE promoter could be explained by the loss of a
nuclear localization signal. The intracellular distribution of
the EICP27 protein derivatives within RK-13 cells trans-
fected with each of the EICP27 expression plasmids was
assessed by indirect immunofluorescence (IF) microscopy.
As shown in Fig. 4A, the anti-EICP27 protein antiserum
showed a punctate staining pattern of the EICP27 protein
within the nuclei of EHV-1-infected cells. The NLS was
subsequently mapped by examining the intracellular distri-
bution of each EICP27 polypeptide in cells transfected with
the corresponding EICP27 expression plasmids. The data
demonstrated that the full-length EICP27 protein as well as
the EICP27 polypeptide that contained residues 1–281
localized within the nucleus. The EICP27 polypeptides that
lacked residues 41–279 or 140–220 accumulated within the
cytoplasm of transfected cells, although the EICP27D47–
140 polypeptide efficiently entered the nucleus. Despite their
small size, the deletion mutants EICP27D41–279 (25.5 kDa)
and EICP27D140–220 (42.9 kDa) failed to enter the nucleus,
suggesting that residues 140–220 harbor an NLS.
To elucidate further the NLS, the intracellular distribu-
tion of several EICP27 linker insertion mutants was exam-
ined by IF microscopy (Fig. 4B). The linker insertion
mutants harbor a BglII linker encoding the four aa sequence
Gly-Cys-Thr-Thr. The presence of the BglII linker should
generate conformational changes in the EICP27 proteinwithin the region that spans the insertion site for the linker
sequence. The results of these assays demonstrated that the
EICP27in140, EICP27in151, and EICP27in220 polypepti-
des localized within nuclear punctuate foci similar to that
observed for the full-size EICP27 protein. However, the
EICP27in176 polypeptide failed to localize within the
nucleus, suggesting that the BglII linker insertion at codon
176 disrupted its NLS function.
To delineate the minimal NLS, sequences encoding
EICP27 residues 1–470, residues 140–220, or portions of
this region were cloned in-frame with a sequence encoding
the green fluorescent protein (GFP). The data obtained from
fluorescence microscopy of the expression of these GFP-
EICP27 fusion plasmids in transfected RK-13 cells are shown
in Fig. 4C. The micrographs revealed punctuate accumula-
tions of the GFP-EICP27(1–470) within the nucleus as was
observed by IF microscopy of the nuclear localization of the
EICP27 protein in cells either infected with EHV-1 or trans-
fected with the pSVEICP27 expression plasmid (Fig. 4A). In
addition, EICP27 residues 140–220 and residues 176–216
also mediated the nuclear accumulation of the GFP fusion
protein; however, the nuclear distribution of these GFP-
EICP27 fusion proteins was more diffuse than the punctuate
nuclear pattern observed for the GFP-EICP27(1–470) fusion
protein. Sequence analysis of residues 176–216 (176-
VARVHRNRRRGNA NHGSNTPGRSAGDRLNAAAAR-
SIADVCR-216) revealed an arginine-rich stretch of basic
residues within codons 176–188 (underlined). The aa com-
position of this sequence closely resembles the requirements
of polybasic nuclear localization signals (such as arginine-
rich sequences) (Christophe et al., 2000), suggesting the
possibility that this sequence mediates the nuclear entry of
the EICP27 protein. Indeed, the GFP-EICP27(178–185)
Fig. 4. Mapping the EICP27 nuclear localization signal (NLS). (A) Indirect immunofluorescence microscopy to detect the intracellular distribution of the full-
length EICP27 protein and its mutant polypeptides. The controls included RK-13 cells mock-infected or infected with EHV-1 (strain KyA) at an MOI of 5 pfu
per cell. RK-13 cells were transfected with 7.5 pmol of either the empty SV-Sport 1 cloning plasmid, or the EICP27 expression plasmids pSVEICP27(1–470),
pSVEICP27(1–281), pSVEICP27D41–279, pSVEICP27D47–140, and pSVEICP27D140–220. At 24 h post-transfection and 6 h post-infection, the cells
were processed for immunofluorescence microscopy as described in Materials and methods. (B) Indirect immunofluorescence microscopy to detect the
intracellular distribution of the native EICP27 protein and its linker insertion mutants at 24 h post-transfection. RK-13 cells were transfected with 7.5 pmol of
either the empty SV-Sport 1 cloning plasmid or the EICP27 expression plasmid pSVEICP27(1–470), pSVEICP27in140, pSVEICP27in151, pSVEICP27in176,
and pSVEICP27in220. (C) Mapping the minimal NLS within the EICP27 protein. The entire EICP27 protein or portions of the EICP27 protein were
synthesized as fusion proteins with the green fluorescent protein (GFP). RK-13 cells were transfected with 7.5 pmol of either the empty pEGFP-C3 cloning
plasmid, or one of the EICP27 expression plasmids pGFP-EICP27(1–470), pGFP-EICP27(140–220), pGFP-EICP27(176–216), and pGFP-EICP27(178–
185). At 24 h post-transfection, fluorescence microscopy assessed the ability of the encoded EICP27 sequence to localize the GFP moiety to the nucleus. DAPI
(blue fluorescence) was included in the mounting solution to visualize the nuclei (as shown in the bottom row of panel C).
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efficiently localized within the nucleus, but did not show a
punctuate staining pattern similar to that observed with the
GFP-EICP27(1–470) fusion protein. The diffuse nuclear
distribution of some GFP fusion proteins was not surprising
as these proteins express only 2–17% of the 470 residues of
the full-length EICP27 protein. Overall, these studies indicate
that the arginine-rich sequence spanning EICP27 residues
178–185 functions as an NLS.
The EICP27 protein does not contain an independent
trans-activation domain
The ability of the EICP27 protein to enhance IE promoter
activity may be ascribed to the function of an independent
trans-activation domain (TAD) within the region spanning
aa 279–470. To test whether the EICP27 protein contains a
TAD, the mammalian Gal4 two-plasmid system wasemployed as used previously to map the TAD of other
herpesvirus regulatory proteins (Perera et al., 1994; Smith et
al., 1994; Xiao et al., 1997). The native EICP27 gene as
well as portions of this gene was cloned in-frame with the
sequence encoding the Gal4 DNA-binding domain (Fig.
5A). Analyses of the expression of these constructs in
transfected RK-13 cells by Western blot and IF microscopy
revealed that the Gal4-EICP27 fusion proteins were synthe-
sized, were of the expected sizes (Fig. 5C), and localized to
the nuclei (Fig. 5B). The Gal4 fusion proteins accumulated
within the nuclei because of an NLS within the Gal4 DNA-
binding domain, which could compensate for the NLS of the
EICP27 protein. The Gal4-EICP27 fusion constructs were
then analyzed for their ability to activate expression of a
Gal4 responsive promoter. Whereas the positive controls,
Gal4-HSV-1 VP16 and Gal4-EHV-1 IE(3–89), efficiently
activated expression of the CAT reporter, the Gal4-EICP27
fusion proteins failed to generate CAT activity (Fig. 5D).
Fig. 5. Assessment of the EICP27 protein for an independent TAD by the Gal4 two-plasmid system. (Panel A) A schematic showing the Gal4-EICP27 fusion
proteins (also designated GalE27) tested for their ability to trans-activate the Gal4-responsive promoter within the pG5EC reporter plasmid. The EICP27
residues present within each Gal4 fusion protein are indicated at the left of the schematic. (Panel B) The synthesized Gal4-EICP27 fusion proteins localized
within the nuclei of transfected cells. RK-13 cells were transfected with 7.5 pmol of either the empty pBxG2V cloning plasmid or one of the EICP27 expression
plasmids pGalE27(8–470), pGalE27(8–279), and pGalE27(279–470). At 24 h post-transfection, the cells were processed for immunofluorescence
microscopy as described in Materials and methods. (Panel C) Western blot analysis with the anti-GST-EICP27 antibody revealed that the Gal4-EICP27 fusion
proteins were stably synthesized at the expected sizes in transiently transfected L-M cells. The sizes of the molecular weight markers (kDa) are indicated at the
left of the panel. (Panel D) Transient transfection assays demonstrated that the Gal4-EICP27 fusion proteins (Bars 5 to 7) failed to activate the Gal4-responsive
promoter within the pG5EC reporter construct. L-M cells were transfected with 1.4 pmol of pG5EC alone (Bar 1) or were cotransfected with the pG5EC
reporter plasmid and 0.3 pmol of either the empty pBxG2V cloning plasmid (Gal4 DNA-binding domain alone, Bar 2), pGal4-HSV-1 VP16 (Bar 3), pGal4-
EHV-1 IE(3–89) (Bar 4), pGal4E27(8–470) (Bar 5), pGal4E27(8–279) (Bar 6), or pGal4E27(279–470) (Bar 7). The data were compiled from the averages of
three independent experiments in which each sample was assessed independently in triplicate. The error bars indicate the standard deviations.
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harbor a trans-activation domain, and thus suggest that the
inability of some of the EICP27 deletion mutants to increase
expression from the IE promoter is not attributed to the
deletion of a TAD.
The EICP27 protein directly interacts with TATA
box-binding protein
The IE protein trans-activates EHV-1 early and late
promoters via a mechanism that involves its interaction
with TBP and TFIIB (Albrecht et al., 2003; Jang et al.,
2001). The cooperation between the EICP27 and the IE
proteins may be due to the ability of the EICP27 protein
to stabilize the interactions of the IE protein with cellular
TBP and TFIIB (Smith et al., 1993b; Zhao et al., 1995).
One prediction of this model would be that the EICP27
protein directly associates with one or both of these
transcription factors. The demonstration that the EICP27protein interacts with one or both of these transcription
factors, possibly within the RNA polymerase II preinitia-
tion complex, would elucidate one mechanism by which
this viral protein stimulates gene expression. To test this
possibility, GST-pulldown assays were performed to de-
termine whether the GST-EICP27(1–470) protein precip-
itated 35S-labeled TBP and 35S-labeled TFIIB from in vitro
transcription/translation reactions. The data indicated that
GST-EICP27(1–470) selectively interacts with 35S-TBP,
but not with 35S-TFIIB (Fig. 6A). To ascertain whether
the EICP27 protein directly interacts with TBP, GST-
pulldown assays that employed purified, full-length
GST-EICP27 protein and purified TBP were performed.
Purification of GST-EICP27 protein and TBP is described
in Materials and methods. The presence of purified TBP
within the precipitated GST-EICP27 fusion protein com-
plexes was determined by Western blot analysis with an
anti-TBP monoclonal antibody. The results showed that
GST-EICP27(1–470) directly precipitated a considerable
Fig. 6. The EICP27 protein directly interacts with TBP. (Panel A) GST-pulldown assays examined the ability of purified GST-EICP27 protein to precipitate 35S-
labeled TFIIB or 35S-labeled TBP from in vitro transcription/translation reactions. Input lanes indicate the amount of 35S-labeled TFIIB or TBP present within
each reaction, which served to assess the relative binding efficiency of each GST fusion protein. (Panel B) Western blot analysis with an anti-TBP antibody
revealed that purified GST-EICP27 protein directly precipitated purified recombinant TBP. The input lane indicates the amount of purified recombinant TBP
present within each reaction, which served to assess the relative binding efficiency of each GST fusion protein. The sizes of the molecular weight markers
(kDa) are indicated at the left of each panel. (Panel C) Co-immunoprecipitation of the EICP27 protein with TBP. Co-immunoprecipitation assays were
performed to ascertain whether an anti-TBP polyclonal antibody co-immunoprecipitated 35S-labeled TBP with either 35S-labeled luciferase (negative control,
lane 6), 35S-labeled TFIIB (positive control, lane 7), or 35S-labeled EICP27(1–470) (lane 8). Some of the reactions (lanes 9 and 10) included pre-immune sera
that served as a control for the specificity of the anti-TBP polyclonal antibody. The input lanes [luciferase, lane 2; TBP, lane 3; TFIIB, lane 4; and EICP27(1–
470), lane 5] contain 50% of the amount of 35S-labeled protein included in the co-immunoprecipitation reactions and served to indicate the efficiency with
which TBP co-immunoprecipitated with the test proteins. The sizes of the molecular weight markers (kDa) are indicated at the left of each panel (lane 1).
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precipitated only a trivial amount of the purified TBP.
Co-immunoprecipitation assays were conducted as an
alternative approach to validate the results of the GST-pull-
down experiments that demonstrated a direct interaction
between the EICP27 protein and TBP (Fig. 6C). In these
assays, 35S-labeled TBP was examined for its co-immuno-
precipitation with 35S-labeled luciferase (negative control),
35S-labeled TFIIB (positive control), and the 35S-labeled
EICP27(1–470) protein. The negative control reaction indi-
cated that the anti-TBP polyclonal antibody failed to co-
immunoprecipitate 35S-TBP and 35S-luciferase (Fig. 6C, lane
6). However, the positive control reaction showed that the
anti-TBP antibody co-immunoprecipitated 35S-TBP and 35S-
TFIIB (Fig. 6C, lane 7). More importantly, the results
demonstrated that the anti-TBP antibody efficiently co-immunoprecipitated 35S-TBP and the 35S-EICP27(1–470)
protein (Fig. 6C, lane 8), thus confirming the interaction of
these two proteins. Additional negative controls demonstrat-
ed that pre-immune serum failed to co-immunoprecipitate
35S-TBP with 35S-TFIIB (Fig. 6C, lane 9) or 35S-TBP with
the 35S-EICP27(1–470) protein (Fig. 6C, lane 10).
EICP27 residues 124–220 harbor a TBP-binding domain
The domain(s) within the EICP27 protein that mediates
its interaction with TBP was mapped by a series of GST-
pulldown assays. In these assays, GST-TBP precipitated a
minimal amount of the 35S-luciferase protein, which was
employed as a negative control (Fig. 7). GST-TBP was
next tested for its ability to precipitate 35S-labeled full-
length EICP27 protein and EICP27 deletion and trunca-
Fig. 7. Mapping the EICP27 sequences necessary for its interaction with TBP. GST-pulldown assays examined the ability of GST-TBP to precipitate the native
EICP27 protein and EICP27 truncation and deletion polypeptides synthesized by in vitro transcription/translation reactions. The input lanes indicate the amount
of each 35S-labeled EICP27 polypeptide present within each reaction, which served to assess the relative binding efficiency of each GST fusion protein. The
sizes of the molecular weight markers (kDa) are indicated at the left of each panel.
Fig. 8. EICP27 residues 93–140 are necessary for its activation of the early
EICP0 promoter. Transient transfection assays assessed whether the
EICP27D93–140 mutant that lacks the TBP-binding domain activated the
EICP0 promoter as efficiently as did the full-length EICP27 protein. L-M
cells were transfected with 1.4 pmol of the reporter plasmid pEICP0-CAT
[pEICP0( 335/ 21)] alone (Bar 1) or were cotransfected with the reporter
plasmid and 0.3 pmol of one of the effector plasmids pSVIE (Bar 2),
pSVEICP27 (Bar 3), or pSVEICP27D93–140 (Bar 4). The data were based
on the averages of three independent experiments in which each sample was
assessed independently in triplicate. The data are presented as the average
percent acetylation of the total amount of 14C-labeled chloramphenicol that
was included in each reaction. The error bars indicate the standard deviations.
R.A. Albrecht et al. / Virology 324 (2004) 311–326318tion polypeptides. The data revealed that GST-TBP precipi-
tated radiolabeled full-size 35S-EICP27(1–470) as well as
35S-EICP27(1–422), 35S-EICP27(1–281), 35S-EICP27D8–
59, 35S-EICP27D41–89, and 35S-EICP27D89–124 polypep-
tides with comparable efficiencies (Fig. 7). However, GST-
TBP was incapable of precipitating the deletion mutants
35S-EICP27D93–140 and 35S-EICP27D140–220. Overall,
these findings indicate that EICP27 residues 124–220 medi-
ate its direct interaction with TBP.
The TBP-binding domain is important for the EICP27
protein to activate the EICP0 promoter
Transient transfection assays demonstrated that deletion of
EICP27 residues 93–140 attenuated the ability of the EICP27
protein to activate the IE promoter by 68% (Fig. 3). An
additional experiment was conducted to determine whether
deletion of residues 93–140 also attenuated the ability of the
EICP27 protein to activate EHV-1 promoters in addition to
the IE promoter. These assays examined whether the
EICP27D93–140 mutant was impaired in activating expres-
sion of the EICP0 promoter-CAT reporter chimera, which
harbors the EICP0 promoter sequence335 to21, relative
to the translation initiation site. As shown in Fig. 8, the IE
protein that served as the positive control stimulated a 45-fold
increase in reporter expression from the EICP0 promoter
(Fig. 8, Bar 2). The full-length EICP27 protein also enhanced
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3). However, removal of residues 93–140 from the EICP27
protein attenuated the ability of this EICP27 mutant to
stimulate this EHV-1 promoter by approximately 71% (Fig.
8, Bar 4). Collectively, the results of the transient transfection
assays that employed the IE and early EICP0 promoters
suggest that residues 93–140 that contribute to the TBP-
binding domain of the EICP27 protein are important for this
protein to stimulate representative EHV-1 promoters.Discussion
Prior investigation of the EHV-1 EICP27 protein
revealed that it independently increased expression from
the IE promoter, but failed to activate early or late viral
promoters (Smith et al., 1993b). These experiments also
showed that the EICP27 protein cooperated with either the
IE or EICP0 protein to trans-activate representative early
and late viral promoters (Bowles et al., 2000; Smith et al.,
1993b; Zhao et al., 1995). These results suggest little about
the exact function of the EICP27 protein during infection,
except that it serves as an early auxiliary regulatory protein.
To elucidate the functional domains of the EICP27 protein,
EICP27 deletion and truncation mutants were examined in
transient transfection assays for their ability to activate the
IE promoter. The data illustrated that removal of aa 140–
220 or 279–470 rendered the EICP27 protein inactive. A
possible explanation for the loss of function of some
EICP27 deletion mutants is the absence of an NLS, which
was mapped in this study to lie within aa 178–185. These
residues may provide another function other than serving as
a nuclear localization signal. Studies on the nuclear entry of
proteins revealed that 50 kDa is the upper size limit that
allows the unrestricted diffusion of proteins across the
nuclear membrane (reviewed in Macara, 2001). Because
the full-length EICP27 protein (51 kDa) and the GFP-
EICP27 fusion proteins (approximately 30 kDa each) accu-
mulated within nuclei, residues 178–185 may function as a
nuclear retention signal. Commonly, an NLS is composed of
either a short stretch of polybasic residues or two clusters of
basic residues separated by a minimal cluster of uncharged
residues (Christophe et al., 2000). In the case of the EICP27
protein, the arginine/glycine-rich residues within aa 176–
188 were shown to be necessary to mediate nuclear entry. In
the case of the HSV-1 ICP27 protein, the first arginine-rich
domain (RGG box, aa 139–153) did not function as an
independent NLS, but contributed to the nucleolar localiza-
tion of this immediate-early protein (Hibbard and Sandri-
Goldin, 1995; Mears et al., 1995).
The EICP27 homologues of the alphaherpesviruses ap-
pear to vary considerably in their functions in virus gene
regulation. For example, the EICP27 gene of EHV-1 is an
early gene (Zhao et al., 1992), whereas its homologues in
HSV-1 and VZVare immediate-early genes (Defechereux et
al., 1997; Honess and Roizman, 1974). Our observation thatthe early EICP27 protein does not contain an independent
trans-activation domain differs from the findings for the
immediate-early IE4 protein of VZV (Perera et al., 1994).
Although Perera et al. demonstrated the IE4 gene product
activated reporter expression in the Gal4 two-plasmid sys-
tem, the authors did not map the minimal domain that
mediates this activation function. Additional investigations
revealed that the IE4 protein increased transcription from
heterologous HIV-1 and SV40 promoters, and that this
function of the VZV protein required cis-acting binding sites
for cellular factors, such as NF-nB and Sp1 (de Maisieres et
al., 1998; Perera et al., 1994). In the case of HSV-1, the ICP27
protein governs gene expression by several mechanisms that
include: (i) an interaction with RNA polymerase II (Zhou and
Knipe, 2002); (ii) an RNA-binding activity (Brown et al.,
1995; Ingram et al., 1996; Mears and Rice, 1996; Sandri-
Goldin, 1998); (iii) the preferential export of viral transcripts
into the cytoplasm (i.e. the leaky-late UL24 transcript) (Pear-
son et al., 2004; Phelan and Clements, 1997; Phelan et al.,
1996; Sandri-Goldin, 1998; Soliman et al., 1997); (iv) the
regulation of pre-mRNA processing (Bryant et al., 2000,
2001; Hann et al., 1998; Hardy and Sandri-Goldin, 1994;
McGregor et al., 1996; McLauchlan et al., 1992); and (v) the
redistribution of cellular factors that mediate RNA-splicing
and mRNA export (Phelan et al., 1993; Sandri-Goldin et al.,
1995). The consequences of these functions of the ICP27
protein are that late gC and UL47 genes and early genes
encoding factors involved in HSV-1 DNA replication are
efficiently expressed (Jean et al., 2001;McCarthy et al., 1989;
Rice and Knipe, 1990; Rice et al., 1989; Sacks et al., 1985;
Uprichard and Knipe, 1996). Association of the ICP27
protein with RNA polymerase II combined with its necessity
for the efficient transcription of the late gC and UL47 genes
suggests that this protein directly stimulates transcription
from HSV-1 promoters. However, a recent study revealed
that the HSV-1 ICP27 protein increases gC gene expression
posttranscriptionally in a manner that is dependent on
sequences within the gC open reading frame, but is not
dependent on the regulatory elements of the gC gene (i.e.
the promoter and polyadenylation site) (Perkins et al., 2003).
To date, studies in this laboratory indicate that the EHV-1
EICP27 protein does not function as a major RNA-binding
protein and appears not to shuttle viral transcripts from the
nucleus. These differences between the EICP27 protein and
HSV-1 ICP27 protein are not surprising because the proteins
exhibit only 32% identity at the amino acid level.
Recent studies revealed that the EHV-1 IE and early
EICP0 regulatory proteins have an antagonistic relationship,
possibly due to their competition for binding to cellular
transcription factors, such as TBP and TFIIB (Albrecht et
al., 2003; Jang et al., 2001; Kim et al., 2003). As noted above,
the EICP27 protein functions in a cooperative manner with
either the IE or the EICP0 protein (Smith et al., 1993b; Zhao
et al., 1995), and this cooperation may involve the EICP27
protein stabilizing the interaction between these viral proteins
and a subset of cellular transcription factors. Evidence
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tein interaction studies that revealed that EICP27 residues
124–220 interact directly with purified TBP. The VZV IE4
protein also associates with TBP, suggesting that the interac-
tion of these herpesviral proteins with cellular transcription
factors contributes to their regulatory roles. In this regard,
TBP is a component of TFIID and recognizes the cognate
TATA box element, and initiates the assembly of the RNA
polymerase II preinitiation complex (Hampsey, 1998). The
recruitment of TFIID to promoters is an absolute requirement
for transcription, in that artificial tethering of TBP to pro-
moters is sufficient to initiate transcription (Gonzalez-Couto
et al., 1997; Huh et al., 1999; Xiao et al., 1995). Numerous
viral regulatory proteins target TBP as a means to regulate
transcription of viral promoters (Abmayr et al., 1988; Car-
rozza and DeLuca, 1996; Caswell et al., 1993; Damania et al.,
1998; Grondin and DeLuca, 2000; Hall et al., 1999; Ingles et
al., 1991; Lieberman and Berk, 1991; Lieberman et al., 1997;
Qadri et al., 1995; Smith et al., 1993a). The binding of viral
trans-activators to TBP results in the: (i) preferential assem-
bly of the preinitiation complex on viral promoters (Lieber-
man et al., 1997), (ii) increased stability of the TFIID-TFIIA
complex on viral promoters (Abmayr et al., 1988; Damania et
al., 1998; Grondin and DeLuca, 2000; Smith et al., 1993a),
and (iii) increased reinitiation of transcription by stabilizing
the transcription intermediate composed of TFIID, TFIIA,
TFIIH, TFIIE, and Mediator (Yudkovsky et al., 2000).
Although the EICP27 protein does not possess an inde-
pendent TAD, it appears to stimulate promoter activity by
binding to TBP and perhaps stabilizing the association of
TBP with the IE protein and other general transcription
factors. The EICP27 protein failed to bind directly to TFIIB;
however, one consequence of its interaction with TBP is that
this viral protein may associate indirectly with other cellular
and viral transcription factors, such as TFIIB and the EHV-1
IE protein. Whether an interaction between the EICP27 and
IE proteins influences the DNA-binding activity of the IE
protein or the interactions of the IE protein with general
transcription factors will be assessed in future studies. In
this regard, our recent studies indicate that a physical
interaction does occur between the IE and EICP27 proteins
(R.A. Albrecht and D.J. O’Callaghan, unpublished obser-
vations). As a result of its interaction with TBP, the EICP27
protein might also stabilize the TFIID-TFIIA transcription
reinitiation intermediate or promote transcription elongation
by RNA polymerase II. These and other questions about the
role of the EICP27 protein in EHV-1 gene programming are
being addressed at the present time.Materials and methods
Virus and cell culture
EHV-1 (KyA strain) was passaged in murine fibroblast L-
M cells as described previously (Perdue et al., 1974). L-Mcells were expanded as suspension cultures in YELP medium
[Eagle’s minimum essential medium (EMEM) supplemented
with yeast extract, lactalbumin hydrolysate, and peptone]
with 100 units of penicillin/ml, 100 Ag of streptomycin/ml,
nonessential amino acids, and 5% fetal bovine serum (FBS).
Rabbit kidney cells (RK-13 cells; ATCC CCL 37) and equine
transitional cell carcinoma (ETCC) cells (Kim et al., 2003)
were grown as monolayer cultures in EMEM supplemented
with 100 units of penicillin/ml, 100 Ag of streptomycin/ml,
nonessential amino acids, and 5% FBS.
Plasmid construction
Cloning of the expression plasmids was performed
according to standard procedures (Sambrook et al., 1989).
The mammalian expression plasmid pSVEICP27 (formerly
pSVUL3) that encodes EICP27 aa 1–470 was described
previously (Smith et al., 1993b; Zhao et al., 1995). pGex-
EICP27(1–470), which expresses the EICP27 gene as a
GST fusion protein, was created by digesting pSVEICP27
with EcoRI and HindIII. The resulting enzyme fragment
was then cloned into the EcoRI and HindIII sites of pGex-
Kg (Guan and Dixon, 1991).
EICP27 truncation and deletion mutants
pSVEICP27D41–89 is a product of the EICP27 linker
insertion mutants pSVEICP27in41 and pSVEICP27in89.
pSVEICP27in41 was cloned by inserting the 12-bp BglII
linker 5V-d(pGGAAGATCTTCC)-3V(New England Biolabs,
Beverly, MA) into the HincII site of pSVEICP27 (codon 41).
pSVEICP27in89 was cloned by inserting a BglII linker into
theHaeIII site of pSVEICP27 (codon 89). pSVEICP27D41–
89 was generated by ligating the EcoRI–BglII fragment of
pSVEICP27in41 with the EcoRI–BglII digestion product of
pSVEICP27in89. pSVEICP27D41–279 is a derivative of
pSVEICP27in41 and pSVEICP27in279. pSVEICP27in279
was cloned by inserting a BglII linker at the HincII site of
pSVEICP27 (codon 279). pSVEICP27D41–279 was subse-
quently generated by ligating the EcoRI–BglII fragment of
pSVEICP27in41 with the EcoRI –BglII fragment of
pSVEICP27in279. pSVEICP27D89–124 was cloned by
self-ligation of the NaeI restriction enzyme digestion product
of pSVEICP27. pSVEICP27D93–140 is a derivative of the
linker insertion mutants pSVEICP27in93 and pSVEIC-
P27in140. pSVEICP27in93 was cloned by inserting a BglII
linker into the HaeIII site of pSVEICP27 (codon 93).
pSVEICP27in140 was cloned by inserting a BglII linker into
the RsaI site of pSVEICP27 (codon 140). pSVEICP27D93–
140 was subsequently cloned by ligating the EcoRI–BglII
fragment of pSVEICP27in93 to the EcoRI–BglII fragment of
pSVEICP27in140. pSVEICP27D93–220 was derived from
the plasmids pSVEICP27in93 and pSVEICP27in220.
pSVEICP27in220 was created by inserting a BglII linker into
the AluI site of pSVEICP27 (codon 220). pSVEICP27D93–
220 was subsequently cloned by ligating the EcoRI–BglII
fragment of pSVEICP27in93 to the EcoRI–BglII fragment of
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the linker insertion mutants pSVEICP27in140 and pSVEIC-
P27in220. pSVEICP27in140 was cloned by inserting
a BglII linker at RsaI site of pSVEICP27 (codon 140).
pSVEICP27D140–220 was derived by ligating an EcoRI–
BglII fragment of pSVEICP27in140 with EcoRI–BglII
digested pSVEICP27in220. pSVEICP27D216–446 was
cloned by digesting pSVEICP27 with PstI at codons 216
and 446, and the resulting fragment was self-ligated.
pSVEICP27D291–343 is a derivative of the EICP27 linker
insertion mutants pSVEICP27in291 and pSVEICP27in343.
pSVEICP27in291 was generated by inserting a BglII linker
into the HaeIII site of pSVEICP27 (codon 291). pSVEIC-
P27in343 was produced by inserting a BglII linker into the
HaeIII site of pSVEICP27 (codon 343). pSVEICP27D291–
343 was cloned by ligating the EcoRI–BglII fragment of
pSVEICP27in291 to the EcoRI–BglII digested pSVEIC-
P27in343. pSVEICP27D343–395 was derived from the
plasmids pSVEICP27in343 and pSVEICP27in395. pSVEIC-
P27in395 was generated by inserting a BglII linker into the
AluI site of pSVEICP27 (codon 395). pSVEICP27D343–395
was subsequently cloned by ligating the EcoRI–BglII frag-
ment of pSVEICP27in343 with the EcoRI–BglII fragment of
pSVEICP27in395. pSVEICP27D380–402 was cloned by a
multistep process. First, the EHV-1 subgenomic plasmid
pHAwas digested with AcyI and self-ligated to create pdHA.
Second, pdHA and pSVUL3EH (Zhao et al., 1995) were
digested with HindIII. Finally, the HindIII fragment of
pdHA was ligated to the HindIII site of pSVUL3EH.
pSVEICP27(1–281) was cloned by partially digesting
pSVEICP27 with RsaI and inserting a 14-bp XbaI oligonu-
cleotide linker 5V-d(pCTAGTCTAGACTAG)-3V (New Eng-
land Biolabs), which contains an amber codon in all three
reading frames, at codon 282. pSVEICP27(1–422) was
generated by partially digesting pSVEICP27 with RsaI, and
inserting a 14-bp XbaI oligonucleotide linker at codon 423.
GFP-EICP27 fusion vectors
pGFP-EICP27(1–470) was created by cloning the
EcoRI–BamHI fragment of pSVEICP27 into the same sites
of pEGFPC3 (Clontech, Palo Alto, CA). pGFP-
EICP27(140–216) was generated by first PCR amplifying
the EICP27 sequence that encoded aa 140–216 with the
forward primer NLS1 and reverse primer NLS3. The forward
and reverse primer sequences weremodified to introduce new
RsaI and XbaI restriction enzyme sites (sites are underlined in
each respective primer; see below) into the EICP27 sequence.
The PCR reaction product was digested with the restriction
enzymes RsaI and XbaI, and the resulting fragment was
cloned into the SmaI and XbaI sites of pEFGP-C1 (Clontech).
pGFP-EICP27(176–216) was produced by PCR amplifica-
tion of codons 176–216 with the forward primer NLS2 and
the reverse primer NLS3. The resulting PCR product was
digested with BalI and PstI, and the enzyme fragment was
cloned into the ScaI and PstI sites of pEFGP-C3. pGFP-
EICP27(178–185) was created by a multistep process. First,50 Ag each of the oligonucleotide 178–185 and its reverse
complement oligonucleotide were mixed in annealing buffer
[20 mMTris–HCl (pH7.4), 2 mMMgCl2, and 50mMNaCl].
The oligonucleotides were annealed by incubating the reac-
tion at 95 jC for 3 min, incubating at 65 jC for 5 min, and
finally allowing the reaction to cool to room temperature. The
oligonucleotides encompassed codons 171–192 of the
EICP27 open reading frame. The EICP27 sequence was
modified to include sequences for the XhoI and BamHI
restriction enzymes (underlined in the sequence) to facilitate
cloning of EICP27 codons 178–185 into the XhoI and
BamHI sites of pEGFPC3.
Gal4-EICP27 fusion vectors
pGalEICP27(8–470) was constructed by cloning the
PvuII–XbaI fragment from pXbaI-G (Zhao et al., 1992)
into the EcoRV–XbaI sites of pBxg2V (Smith et al., 1994).
pGalEICP27(8–279) was generated by cloning the PvuII–
HpaI fragment from pXbaI-G into the EcoRV site of
pBxg2V. pGalEICP27(279–470) was produced by cloning
the HpaI–BglII fragment from pXbaI-G into the SmaI–BclI
sites of pBxg1 (Smith et al., 1994). The pGal4-HSV-1 VP16
and pGal4-EHV-1 IE(3–89) expression constructs as well
as the Gal4 responsive CAT reporter, pG5EC, were de-
scribed elsewhere (Smith et al., 1994).
EICP27 in vitro transcription/translation expression
plasmids
pGemEICP27(1–470) was constructed by digesting
pSVEICP27 with EcoRI and SphI, and ligating the resulting
fragment with pGem7z (Promega, Madison, WI) that
was digested with EcoRI and SphI. pGemEICP27(1–422)
was generated by inserting the EcoRI–SphI fragment
of pSVEICP27(1–422) into the same sites of pGem7z.
pGemEICP27(1–281) was created by subcloning the
EcoRI–SphI fragment of pSVEICP27(1–281) into the
same sites of pGem7z. The plasmids pGemEICP27D41–
89, pGemEICP27D93 – 140, pGemEICP27D89 – 124,
and pGemEICP27D140–220 were created by subcloning
the EcoRI–SphI fragment from the EICP27 expression
plasmids pSVEICP27D41–89, pSVEICP27D93–140,
pSVEICP27D89–124, and pSVEICP27D140–220, respec-
tively, into the EcoRI and SphI sites of pGem3z.
pGemEICP27D8–59 was created by a two-step process.
First, pSVEICP27D8–59 was generated by double digestion
of pSVEICP27 with PvuII and Eco47III, and self-ligating the
resulting restriction enzyme fragment. pGemEICP27D8–59
was then created by subcloning the EcoRI–SphI fragment of
pSVEICP27D8–59 into the same sites of pGem3z.
TATA box-binding protein and TFIIB plasmids
pGST-hTBP(1–339) was generated by subcloning the
BamHI–EcoRI fragment containing the TBP open reading
frame from pG3hTBP(1–339) into the same restriction en-
zyme sites of pGEX-Kg. pG3hTBP(1–339) was created by
first PCR amplifying the TBP gene from pQE30-6His-hTBP
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versity of California at LosAngeles, CA). The forward primer
was TBPfor and the reverse primer was TBPrev. The restric-
tion enzyme sites for BamHI and EcoRI within the forward
and reverse primers, respectively, are underlined. The PCR-
amplified TBP open reading frame was digested with BamHI
and EcoRI and was cloned into the same sites in pGem-3z.
The construction of pG3hIIB that expresses full-length TFIIB















Expression and purification of GST fusion proteins
The induction of GST fusion protein synthesis has been
described elsewhere (Jang et al., 2001; Kim et al., 1995). The
pGex plasmids were transformed into the Escherichia coli
BL21(DE3)pLysE strain (Novagen, Madison, WI) or the
trxB(DE3)pLysE strain (Novagen) by heat shock. Following
the induction of protein synthesis, the bacteria were pelleted
and lysed in 10 ml of Bugbuster Reagent (Novagen) supple-
mented with benzonuclease (Novagen) and the protease inhib-
itors PMSF, TPCK, TLCK, and aprotinin (Sigma, St. Louis,
MO). The purification and assessment of the concentration of
the GST-fusion proteins were performed as described else-
where (Jang et al., 2001). To prepare TBP devoid of the GST
fusion tag, GST-TBP was treated with thrombin (Sigma) to
release the GSTmoiety. TBPwas then separated from theGST
moiety by centrifugation in a 30-kDa size exclusion Centricon
spin column (Millipore Corporation, Bedford, MA).
Generation of anti-EICP27 protein polyclonal antiserum
Two New Zealand White rabbits (approximately 3 kg per
rabbit) were each immunized intramuscularly in a hind leg
with 500 Ag of purified GST-EICP27(1–470) diluted in sterile
phosphate-buffered saline (PBS) and emulsified in Freund’s
complete adjuvant. The immunized rabbits were administered
a booster injection of 500 Ag of recombinant protein emulsified
in incomplete Freund’s adjuvant every fourth week for a total
of four booster injections per rabbit. Pre-immune serum and
the anti-GST-EICP27(1–470) antiserum were separated fromthe plasma by storing the blood for 4 h at room temperature,
and then incubating at 4 jC overnight. After removing the clot,
the antiserum was cleared of any remaining blood cells by
centrifugation for 10 min at 2700 rpm in an Allegra 6R
centrifuge (Beckman Coulter, Fullerton, CA).
Plasmid transfection and chloramphenicol
Acetyl-transferase (CAT) assays
The EHV-1 IE promoter-CAT reporter chimera construct,
pIE-CAT [pIE (802/+73)], was described elsewhere (Smith
et al., 1992). The cloning of the EICP0 promoter-CAT
reporter chimera, pEICP0-CAT [pEICP0 (335/21)] was
previously detailed (Buczynski et al., 1999). L-M or RK-13
cells were seeded as monolayers of 5 105 cells per 60-mm-
diameter dish. Transfection of cell monolayers with the
reporter and effector plasmids was performed as described
previously (Holden et al., 1995; Jang et al., 2001). In the
transient transfection experiments that employed the pIE-
CAT reporter, cells were transfected with 0.5 pmol of the IE-
CAT [pIE(802/+73)] reporter plasmid alone or were
cotransfected with the IE-CAT reporter plasmid and 0.3 pmol
of the indicated EICP27 expression plasmid. For the Gal4
two-plasmid assay, cells were transfected with 1.4 pmol of the
pG5EC reporter plasmid alone or were cotransfected with the
pG5EC reporter plasmid and 0.3 pmol of the indicated Gal4
expression plasmid. In the transient transfection assays that
employed the pEICP0-CAT reporter, cells were transfected
with 1.4 pmol of the pEICP0-CAT reporter plasmid alone or
were cotransfected with 1.4 pmol of the pEICP0-CATand 0.3
pmol of one of the effector constructs indicated in the figure
legend. At 48 h post-transfection, the cell monolayers were
harvested, and protein quantitation and CAT assays were
performed as described elsewhere (Holden et al., 1995; Smith
et al., 1992). For each CATassay, every sample was assessed
in triplicate, and each assay was independently repeated at
least thee times. The statistical significance of the data was
determined with the Student’s t test.
Western blot analyses
Western blot analyses was performed as described else-
where (Jang et al., 2001), except for the following mod-
ifications. After washing the membranes 3 with TBST
buffer, the membranes were incubated with either pre-
immune serum, the anti-GST-EICP27 polyclonal antibody
(1–5000 dilution in TBST), or with the anti-TBP monoclo-
nal antibody [1–500 dilution in TBST, BD Biosciences
Pharmingen (Transduction Laboratories), San Diego, CA]
for 1 h at RT.
Fluorescence microscopy
RK-13 cells cultured in two-well Falcon chamber slides
(BD Biosciences) were transfected with 7.5 pmol of the
indicated EICP27 expression plasmids as described above.
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fixation buffer (3% paraformaldehyde and 2% sucrose in
PBS) for 15 min at room temperature. Next, the cells were
incubated in permeabilization buffer (20 mM HEPES, 300
mM sucrose, 50mMNaCl, 3mMMgCl2, and 0.5%Triton X-
100) for 10 min at room temperature and then washed 3
with PBS. To examine the expression of the EICP27 gene and
EICP27 deletion mutants, the wells were incubated with the
anti-GST-EICP27 polyclonal antiserum diluted 1:1500 in
PBS for 1 h at room temperature. After washing the wells
3 with PBS, FITC-conjugated goat anti-rabbit IgG antise-
rum diluted 1:1000 was added, and the slides were incubated
for 1 h at room temperature. IF images were captured with a
Sensys digital camera that was mounted to an Olympus BX50
fluorescent microscope, and the images were analyzed with
the Metamorph analysis software. To examine the expression
of the GFP fusion proteins harboring portions of the EICP27
protein, cells were transfected as described above with the
indicated GFP expression construct. At 24 h post-transfec-
tion, the cells were fixed with 1 ml of fixation buffer, and
coverslips weremounted with the SlowFade antifade solution
containing 4V,6-diamidino-2-phenylindole dihydrochloride
(DAPI), as per the manufacturer’s directions (Molecular
Probes, Eugene, OR). Fluorescence microscopy was per-
formed as described above.
In vitro transcription/translation reactions
The T7 promoter controlled expression of the pGem-
EICP27 derivatives, although the Sp6 promoter regulated
expression from pG3hTBP(1–339) and pG3hIIB. The pro-
teins were synthesized with the TnT-coupled rabbit reticulo-
cyte lysate in vitro transcription/translation (IVTT) kit
(Promega) as per the manufacturer’s directions. To generate
35S-labeled proteins, [35S]methionine (40 ACi/ml; specific
activity, 1175 Ci/mmol; New England Nuclear Corporation,
Boston, MA) was included in the IVTT reactions. The
synthesis of 35S-labeled proteins was assayed by SDS-PAGE
analysis and autoradiography, and the proteins were either
employed in GST-pulldown assays or stored at 20 jC.
GST-pulldown assays
To determine whether the EICP27 protein directly inter-
acts with TBP, GST-pulldown assays were performed as
detailed previously (Jang et al., 2001), with some modifi-
cations of the procedure. One microgram of either GST or
GST-EICP27(1–470) was mixed with 1Ag of GST-free TBP
in 600 Al of NETN buffer [100 mM NaCl, 1 mM EDTA, 20
mM Tris–HCl (pH8.0), and 0.5% NP-40]. The samples
were incubated for 90 min at room temperature, then
supplemented with 40 Al of a 50% mix of GST-Bind resin
(Novagen) and incubated an additional 90 min at room
temperature. The samples were then centrifuged and washed
5 with 600 Al of NETN buffer. Precipitated TBP was
processed for Western blot analysis as described above. Toexamine the interactions of 35S-labeled proteins with GST
fusion proteins in vitro, GST-pulldown assays were per-
formed. Briefly, 2 Ag of either GST alone or a GST fusion
protein was mixed with 35S-labeled proteins in 600 Al of
NETN buffer. The GST-pulldown reactions were processed
as described for the direct interaction assay. The 35S-labeled
proteins that were precipitated by the GST proteins were
analyzed by SDS-PAGE followed by autoradiography using
phosphorstorage screens. The 35S-labeled proteins were
visualized by analyzing the screens in the Storm Phosphor-
Imager (Molecular Dynamics, Amersham Biosciences, Pis-
cataway, NJ).
Co-immunoprecipitation studies
35S-radiolabeled luciferase, 35S-TBP, 35S-TFIIB, and the
35S-EICP27(1–470) protein were produced by in vitro
transcription and translation reactions as described above.
The binding reactions included 10 Al of 35S-labeled TBP
incubated with 10 Al of one of the 35S-labeled proteins
[luciferase, TFIIB, or EICP27(1–470)] diluted in 600 Al of
immunoprecipitation buffer [10 mM Tris–HCl (pH 8.0),
140 mM NaCl, 0.025% NaN3, 0.1% Triton X-100, and 5
mM MgCl2]. Additionally, the binding reactions contained
either 5 Al of the anti-TBP polyclonal antibody (SI-1, Santa
Cruz) or rabbit pre-immune sera. Following an overnight
incubation of the binding reactions at 4 jC, 40 Al of a 50%
slurry of Protein A agarose beads (Sigma) were added to
each reaction. Following a 1.5-h incubation at room tem-
perature, co-immunoprecipitated proteins bound to the Pro-
tein A agarose beads were washed five times with 600 Al of
immunoprecipitation buffer. Following the last wash, the
Protein A agarose beads containing the immunoprecipitated
proteins were processed for SDS-PAGE, and the co-immu-
noprecipitated 35S-labeled proteins were visualized as de-
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